The groundbreaking success of the copyright undeniably reshaped the drug landscape, but investing in companies heavily reliant on off-patent versions presents a complex picture. While early returns were impressive, the expiration of patents and the emergence of discounted alternatives have weakened the customer base. Therefore, a thorough evaluatio